Detalhe da pesquisa
1.
Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study.
Blood
; 141(14): 1675-1684, 2023 04 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36542826
2.
Autologous stem cell transplant in fit patients with refractory or early relapsed diffuse large B-cell lymphoma that responded to salvage chemotherapy.
Haematologica
; 2024 Jan 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38235513
3.
Day 100 Natural Killer Cell/CD14+HLA-DRDIM ratio and survival in lymphoma post-autologous peripheral blood hematopoietic stem cell transplantation.
Clin Transplant
; 38(1): e15211, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38041479
4.
Plain language summary of the TRANSFORM study primary analysis results: lisocabtagene maraleucel as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen.
Future Oncol
; 2024 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38547003
5.
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.
Lancet
; 399(10343): 2294-2308, 2022 06 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-35717989
6.
Consolidative radiotherapy for residual fluorodeoxyglucose activity on day +30 post CAR T-cell therapy in non-Hodgkin lymphoma.
Haematologica
; 108(11): 2982-2992, 2023 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37317888
7.
NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022.
J Natl Compr Canc Netw
; 20(4): 322-334, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35390768
8.
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL.
Blood
; 134(11): 851-859, 2019 09 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31340982
9.
Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type.
Hematol Oncol
; 39(5): 658-663, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34453851
10.
Outcomes of Autologous Stem Cell Transplant Consolidation in Primary Central Nervous System Lymphoma: A Mayo Clinic Experience.
Biol Blood Marrow Transplant
; 26(12): 2217-2222, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32818553
11.
Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma.
Blood
; 132(21): 2240-2248, 2018 11 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-30262659
12.
Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 18(6): 755-781, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32502987
13.
Role of systemic high-dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: A single center experience 1990-2018.
Am J Hematol
; 94(3): 291-298, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30516868
14.
Large B-cell transformation in nodular lymphocyte-predominant Hodgkin lymphoma: 40-year experience from a single institution.
Blood
; 127(16): 1960-6, 2016 Apr 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-26837698
15.
End-of-treatment PET in early-stage Hodgkin lymphoma: valuable in addition to interim PET.
Haematologica
; 108(6): 1697-1701, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36546451
16.
NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018.
J Natl Compr Canc Netw
; 16(3): 245-254, 2018 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-29523663
17.
Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma.
Br J Haematol
; 178(3): 427-433, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28466487
18.
The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma.
Blood
; 126(3): 328-35, 2015 Jul 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-25921059
19.
Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 15(5): 608-638, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28476741
20.
Long-term follow-up of chemoimmunotherapy with rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD) in patients with relapsed CD20+ B-cell non-Hodgkin lymphoma: Results of a study of the Mayo Clinic Cancer Center Research Consortium (MCCRC) MC0485 now known as academic and community cancer research united (ACCRU).
Am J Hematol
; 92(10): 1004-1010, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28614905